TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29450890

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1600 mg once daily
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg once daily
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (historical control)
Number of subjects: 365
Study: 26407253

Group type: EXPERIMENTAL
Intervention: Pleconaril
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24522160

Group type: EXPERIMENTAL
Intervention: Early measles vaccination (MV) at age 4.5 months
Number of subjects: 656

Group type: COMPARATOR
Intervention: Measles vaccination (MV) only at age 9 months
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Early MV in healthy children
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Early MV in ill children
Number of subjects: 656
Study: 22945623

Group type: EXPERIMENTAL
Intervention: 1000‐mg naltrexone implant and oral placebo (NI+OP group; 102 patients)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo implant and 50‐mg oral naltrexone hydrochloride (PI+ON group; 102 patients)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo implant and oral placebo (PI+OP group; 102 patients)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: NI+OP group
Number of subjects: 306

Group type: COMPARATOR
Intervention: PI+ON group
Number of subjects: 306

Group type: COMPARATOR
Intervention: PI+OP group
Number of subjects: 306
Study: 20012501

Group type: EXPERIMENTAL
Intervention: Molecular prediction system based on 22-gene expression profile
Number of subjects: 141
Study: 17564826

Group type: EXPERIMENTAL
Intervention: Capnometry-assisted breathing training for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 12
Study: 16030367

Group type: EXPERIMENTAL
Intervention: Metabolife Ephedra‐Free
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12236827

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish (Cervitec) applied every 3 months
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 181
Study: 10085276

Group type: EXPERIMENTAL
Intervention: 1600 mg SQV/200 mg RTV
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1600 mg SQV
Number of subjects: 20
Study: 8775777

Group type: EXPERIMENTAL
Intervention: Estradiol vaginal ring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 0
Study: 2058588

Group type: EXPERIMENTAL
Intervention: Diet plus endurance exercise and weight training (EEWT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diet plus weight training (WT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diet plus endurance exercise (EE)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Diet only (C)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All groups (C, EE, WT, EEWT)
Number of subjects: 69
Study: 6875802

Group type: EXPERIMENTAL
Intervention: High self-conscious subjects with failure feedback
Number of subjects: 120

Group type: COMPARATOR
Intervention: High self-conscious subjects with success feedback
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low self-conscious subjects
Number of subjects: 120
Study: 31097732

Group type: EXPERIMENTAL
Intervention: Tai Chi training for six months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tai Chi experts
Number of subjects: 75
Study: 29216608

Group type: EXPERIMENTAL
Intervention: Brief need based psychoeducation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 27085785

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALT) levels, adjusted for every standard deviation increase (13.2 U/L)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: γ-glutamyl transferase (GGT) >70 U/L
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: ALT levels (lower levels)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: GGT >70 U/L
Number of subjects: 679
Study: 25134822

Group type: EXPERIMENTAL
Intervention: Provider-initiated HIV testing and counselling (PITC)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Voluntary counselling and testing (VCT)
Number of subjects: 930
Study: 21975559

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg IV infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate (5 mg/day)
Number of subjects: 0
Study: 19843837

Group type: EXPERIMENTAL
Intervention: Patients with at least one unexplained medication discrepancy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Benefit card holders
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Patients prescribed 5 or more drugs at discharge from the ED
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Patients first seen by a physician within 1 hour of a change in working shift
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Each additional minute of wait time for a physician
Number of subjects: 210
Study: 17447275

Group type: EXPERIMENTAL
Intervention: 15-minute hamstring muscle massage
Number of subjects: 11

Group type: COMPARATOR
Intervention: 15-minute prone rest
Number of subjects: 11
Study: 15870639

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heavy exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sprint exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no prior intervention)
Number of subjects: 12
Study: 12067329

Group type: EXPERIMENTAL
Intervention: Auditory brainstem responses (ABRs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Middle-latency responses (MLRs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Slow cortical potentials (SCPs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined ABRs and MLRs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined ABRs and SCPs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined MLRs and SCPs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All three responses (ABRs, MLRs, SCPs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All three responses in patients without neurological signs of brainstem lesion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All three responses in subjects with negative MRI
Number of subjects: 40
Study: 10220831

Group type: EXPERIMENTAL
Intervention: Salivary IL‐6 levels in patients with SS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Salivary IL‐6 levels in patients with dry mouth
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Serum IL‐6 levels in patients with SS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Serum IL‐6 levels in patients with dry mouth
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation between salivary IL‐6 levels and focus score of labial biopsies in SS patients
Number of subjects: 36
Study: 8538437

Group type: EXPERIMENTAL
Intervention: Sensory reeducation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no sensory reeducation)
Number of subjects: 27
Study: 2216622

Group type: EXPERIMENTAL
Intervention: Single-dose surfactant (100 mg/kg of bovine surfactant)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multiple-dose surfactant (100 mg/kg of bovine surfactant, eligible for up to three additional doses)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (air placebo)
Number of subjects: 75
Study: 6257524

Group type: EXPERIMENTAL
Intervention: Bovine synthetic PTH
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Calcitonin (16 salmon, 18 human, 4 porcine)
Number of subjects: 63
Study: 30430605

Group type: EXPERIMENTAL
Intervention: Emricasan 25 mg twice daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29041947

Group type: EXPERIMENTAL
Intervention: FREE approach (intervention arm GPs trained in the FREE approach)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Usual care (control arm GPs continuing to practice as usual)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: FREE approach
Number of subjects: 275

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study: 25468170

Group type: EXPERIMENTAL
Intervention: 6 weeks of antibiotic treatment
Number of subjects: 351

Group type: COMPARATOR
Intervention: 12 weeks of antibiotic treatment
Number of subjects: 351
Study: 23321318

Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg every 8h) with PegIFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo with PegIFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks
Number of subjects: 662
Study: 21454051

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) course
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 20031848

Group type: EXPERIMENTAL
Intervention: Information technology-enhanced care coordination
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 550
Study: 17629162

Group type: EXPERIMENTAL
Intervention: Daflon (500 mg twice/daily for six months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vitamin pill)
Number of subjects: 20
Study: 15140323

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 11249829

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study: 9622407

Group type: EXPERIMENTAL
Intervention: 48-hour change interval
Number of subjects: 76

Group type: COMPARATOR
Intervention: 72-hour change interval
Number of subjects: 76
Study: 7982445

Group type: EXPERIMENTAL
Intervention: Calcium plus 50 IU d‐1, 5 days per week of nasal salmon calcitonin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 100
Study: 3059222

Group type: EXPERIMENTAL
Intervention: WEB 1881 FU (cholinergic nootropic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 239346

Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Propantheline bromide
Number of subjects: 7
Study: 31669921

Group type: EXPERIMENTAL
Intervention: Isometric knee extension contractions at 90° knee flexion
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Rate of torque development (0-100 ms)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Rate of torque development (100-200 ms)
Number of subjects: 52
Study: 28669778

Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diclofenac and Rebamipide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Betamethasone alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Betamethasone and Rebamipide
Number of subjects: 80
Study: 25819462

Group type: EXPERIMENTAL
Intervention: Retosiban
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23454402

Group type: EXPERIMENTAL
Intervention: Desmopressin 50 μg
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Desmopressin 75 μg
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 22142351

Group type: EXPERIMENTAL
Intervention: Carvedilol (80 mg, once daily for 4 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Atenolol (100 mg, once daily for 4 weeks)
Number of subjects: 41
Study: 18647845

Group type: EXPERIMENTAL
Intervention: 4% lidocaine gel
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Acetaminophen, ibuprofen, and/or 4% lidocaine gel
Number of subjects: 418
Study: 16832667

Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of Robert Jones bandage
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of elastic support bandage
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of below-knee plaster cast
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of synthetic below-knee cast
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Frozen ice packs applied to the surface of all bandages and casts
Number of subjects: 44
Study: 12874748

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 220 mg per day for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (dummy pill)
Number of subjects: 15
Study: 11071348

Group type: EXPERIMENTAL
Intervention: Transitions Gray variable tint optics (VTO)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Clear lenses
Number of subjects: 59

Group type: COMPARATOR
Intervention: Fixed-tint lenses
Number of subjects: 59
Study: 9128016

Group type: EXPERIMENTAL
Intervention: Low-dose prostaglandin E1 (PGE1) at a rate of 0.2 microgram.kg‐1.min‐1 throughout surgery
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 109
Study: 8151248

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 3555016

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (slow‐release aspirin and dipyridamole)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vitamin B (Control group)
Number of subjects: 38
Study: 30373567

Group type: EXPERIMENTAL
Intervention: Glucocorticoid-treated group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 150
Study: 27261997

Group type: EXPERIMENTAL
Intervention: Nepeta menthoides Boiss. & Buhse freeze-dried aqueous extract
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 72
Study: 24100074

Group type: EXPERIMENTAL
Intervention: Taloelast(®) anterior elastic ankle-foot orthoses
Number of subjects: 7

Group type: COMPARATOR
Intervention: Shoes only
Number of subjects: 7
Study: 22924259

Group type: EXPERIMENTAL
Intervention: Treatment according to guidelines (British National Formulary - BNF, and Senford Guide)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ordinary treatment
Number of subjects: 100
Study: 20426630

Group type: EXPERIMENTAL
Intervention: Powerlink stent‐graft
Number of subjects: 157
Study: 18481704

Group type: EXPERIMENTAL
Intervention: Patient education by nurses
Number of subjects: 4
Study: 17032157

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy in addition to treatment as usual
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 106
Study: 12743445

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 10669153

Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 20
Study: 9322469

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance with 20 mL bupivacaine 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nerve stimulator (NS) with 20 mL bupivacaine 0.5%
Number of subjects: 40
Study: 8493504

Group type: EXPERIMENTAL
Intervention: Amalgam containing gamma‐2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dimaval (after challenge)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amalgam free of gamma‐2
Number of subjects: 20
Study: 3517650

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30612134

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Diclofenac Sodium (75 mg)
Number of subjects: 400
Study: 28580504

Group type: EXPERIMENTAL
Intervention: Emotion-Focused Cognitive-Behavioral Therapy (ECBT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional Cognitive-Behavioral Therapy (CBT)
Number of subjects: 92
Study: 26322555

Group type: EXPERIMENTAL
Intervention: Caffeine (∼ 5 mg · kg(‐1) body weight)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 24506989

Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Number of subjects: 47
Study: 22913676

Group type: EXPERIMENTAL
Intervention: Late course accelerated hyperfractionated irradiation (LCAF)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: LCAF with concurrent chemotherapy (LCAF + CT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (LCAF)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (LCAF + CT)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Overall group of patients
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Elderly patients (≥ 70 years)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Living patients
Number of subjects: 111
Study: 19969511

Group type: EXPERIMENTAL
Intervention: Preoperative radio-chemotherapy (RCT)
Number of subjects: 21
Study: 17391930

Group type: EXPERIMENTAL
Intervention: donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo donepezil for 12 weeks
Number of subjects: 13
Study: 15359055

Group type: EXPERIMENTAL
Intervention: Advanced practice nursing support (telephone calls from an APN twice in the first week and weekly for 4 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 11260420

Group type: EXPERIMENTAL
Intervention: Venous pressure (VP) monitoring
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Access flow (Qa) monitoring
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Combination of VP and Qa monitoring
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study: 9884779

Group type: EXPERIMENTAL
Intervention: Adhesive precoated brackets (APC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Straight‐Wire brackets with Transbond XT adhesive
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dyna‐Lock brackets with Right‐On adhesive
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Right‐On adhesive
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: APC or Transbond adhesive
Number of subjects: 40
Study: 8004731

Group type: EXPERIMENTAL
Intervention: Awake intubation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intubation following induction of anaesthesia with thiopentone 5 mg.kg‐1 and succinylcholine 2 mg.kg‐1
Number of subjects: 13
Study: 2537830

Group type: EXPERIMENTAL
Intervention: Combined vaccine (C) against yellow fever and measles
Number of subjects: 219

Group type: COMPARATOR
Intervention: Yellow fever vaccine only (A)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Measles vaccine only (B)
Number of subjects: 219
Study: 15231512

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (D2E7, adalimumab, Humira)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31907054

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations
Number of subjects: 5

Group type: COMPARATOR
Intervention: ICS treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control arms (ICS, LABA, and/or placebo)
Number of subjects: 5
Study: 30828762

Group type: EXPERIMENTAL
Intervention: Early treatment with diuretics and vasodilators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novel treatments under development
Number of subjects: 0
Study: 27312250

Group type: EXPERIMENTAL
Intervention: Lifestyle changes (score increase from 0-1 to 2-4)
Number of subjects: 6886

Group type: EXPERIMENTAL
Intervention: Increment in lifestyle score (each point increase)
Number of subjects: 6886

Group type: EXPERIMENTAL
Intervention: One-point increase in lifestyle score from 2001 to 2004
Number of subjects: 6886
Study: 25254357

Group type: EXPERIMENTAL
Intervention: Major bleeding events (PLATO definition)
Number of subjects: 18624

Group type: EXPERIMENTAL
Intervention: Spontaneous bleeding
Number of subjects: 18624

Group type: EXPERIMENTAL
Intervention: Procedure-related bleeding
Number of subjects: 18624
Study: 23751132

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 30
Study: 21534246

Group type: EXPERIMENTAL
Intervention: Blood temperature- and blood volume-control phase (CTL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard phase (STD)
Number of subjects: 26
Study: 19881973

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 200 U/day + physical therapy (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Paracetamol 1,500 mg/day + physical therapy (n = 22)
Number of subjects: 45
Study: 16891222

Group type: EXPERIMENTAL
Intervention: Standard nicotinamide (1.2 g/m2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15574071

Group type: EXPERIMENTAL
Intervention: 7-week interval-training program consisting of 2 specific 30-minute sessions per week of short high-intensity, intermittent-running aerobic exercises at velocities ranging from 100-130% of maximal aerobic speed
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study: 11275164

Group type: EXPERIMENTAL
Intervention: 10 mg extended-release oxybutynin
Number of subjects: 382

Group type: COMPARATOR
Intervention: 4 mg tolterodine (2 mg twice a day)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Both treatment arms combined
Number of subjects: 382
Study: 9223394

Group type: EXPERIMENTAL
Intervention: 400 mg bezafibrate
Number of subjects: 73

Group type: COMPARATOR
Intervention: 10 mg simvastatin
Number of subjects: 73
Study: 8477565

Group type: EXPERIMENTAL
Intervention: 4 mg perindopril once daily
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: 2 mg perindopril twice daily
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 3673751

Group type: EXPERIMENTAL
Intervention: Continuous monitoring (CM)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 296